Press Release
01 Oct, 2019
InnoCare announced that Dr. Xiangyang Chen, who has over 20 years’ experience in biomedical research, was promoted to CTO.
03 Jun, 2019
InnoCare, a leading innovator for global biopharmaceutical drugs, is proud to announce the appointment of Shaojing Tong as Chief Financial Officer (CFO). Mr. Tong has been a leading healthcare research analyst for the Asia-market and has extensive knowledge of the industry. Reporting directly to the CEO, Dr. Jasmine Cui, Mr. Tong will be responsible for the financial strategy development, risk management, and investment analysis. Mr. Tong is considered one of Hong Kong’s top research analysts for the entire biopharmaceutical and healthcare sector, repeatedly being ranked in the “Best Analyst Team” of the Asian healthcare industry. Mr. Tong has many years of experience in managing investment analyst teams and has acquired comprehensive knowledge of the industries history, value chains, and developmental trends. Before joining InnoCare, Mr. Tong served as an executive director and industry analyst at UBS China, where he covered medical companies for both the Hong Kong and A-class China markets. Prior to UBS, Mr. Tong was a healthcare research analyst for Bank of America Merrill Lunch (Hong Kong) and Michael Partners (New York). Preceding his financial career, Mr. Tong worked in drug development for CADUS Pharmaceuticals (New York). Mr. Tong received a Bachelor of Science degree in materials science and engineering from the University of Science and Technology of China. He obtained a Master’s degree in chemistry at the University of Pittsburg, and a Master of Business Administration (MBA) from New York University. “We are very pleased to have Mr. Tong onboard,” said Dr. Cui, CEO and Chairman of InnoCare, “His extensive knowledge and unique insight of the biopharmaceutical industry will help cement a strong financial foundation for InnoCare so that we can continuously build towards our goal of becoming a global leader for innovative drugs.” “I am honored to be a member of InnoCare and work with such an outstanding team,” Mr. Tong said, “InnoCare is a leader among Chinese innovative pharmaceutical companies, establishing a wealth of product pipeline in a very short amount of time. I look forward to joining such an experienced and passionate team, and will advance InnoCare’s goal of providing safe, effective, and affordable drugs for patients around the world.”
09 May, 2019
On May 9th of 2019, InnoCare announced the approval of their proprietary BTK inhibitor ICP-022 by the US Food and Drug Administration (FDA) for initiation of clinical investigations. ICP-022 is the first innovative drug candidate from InnoCare to initiate clinical trials in the US. ICP-022 is a highly selective BTK inhibitor targeting both oncology and autoimmune indications. Currently multi-center, multi-indication phase I/II studies are underway in China, with encouraging preliminary results on safety and efficacy. Following the IND approval, InnoCare will soon conduct the clinical trials in the US for ICP-022. InnoCare will also actively seek collaborations with innovative biotech and pharmaceutical companies in related areas. “This is a major milestone for us. We are fully committed to the global development of ICP-022 and looking forward to the expansion of ICP-022 into global markets.” said Dr. Cui Jisong, co-founder, Chairman, and CEO of InnoCare.
11 Mar, 2019
March 11, 2019, InnoCare announced that Mr. James Deng has accepted the invitation to be its ABM in Sales & Marketing,providing consultancy on launch strategy and commercial operation. As a member of BD Global Operating Committee, Mr. James Deng is the Senior Vice President of BD and General Manager of Greater China. He is also the founding and elected AdvaMed China Board Chair for four consecutive terms. Prior to BD, Mr. James Deng served as VP Marketing in Novartis Pharma US. Before that, he was the CEO & President for Novartis Pharma China, leading Novartis  to be the largest multinational pharmaceutical company with the fastest growing business in China. Under his leadership, the “thick product project” he initiated to optimize the company's infrastructure significantly improved the company's competitiveness. This project was selected as a classic case of Harvard Business School. Mr. James Deng also worked for Johnson & Johnson Pharma in China. He is a graduate of China Europe International Business School (CEIBS) EMBA and General Management Program(GMP) of Harvard Business School. Mr. James Deng now takes active role as Deputy Head of Healthcare Industry Division in China Health Economics Association. “It’s our privilege to have Mr. James Deng to be a key member in InnoCare’s Advisory Board in Sales & Marketing.” Said Dr. Jasmine Cui, Chairman and CEO of InnoCare,” James is a highly respected leader in healthcare industry. His track-record in leading multinational pharma and MedTech companies is resulted from his profound market insights, strong business operation, and global perspective. James’ support will accelerate the pace of InnoCare’s innovative drug products reaching the patients with urgent needs”. “I am truly honored to be a member of InnoCare’s advisory board. As someone who has been working in healthcare for 30years, I have two missions: one is always putting the patient in the center of everything we do, bringing real benefits to them; one is driving true China innovation that can make a global impact. As a leading innovative company in China, InnoCare has done an excellent job in these two aspects. I will contribute as much as I can to support InnoCare become one of the most successful organization in both drug R&D and  commercialization. I believe by doing so, together, we will greatly benefit patients in China and worldwide”.
20 Jul, 2018
On July 20, 2018, InnoCare announced an agreement between Beijing InnoCare Pharma Tech Co., Ltd., Guangzhou Development Zone, and its subsidiary Guangzhou Kaide Technology Development Co., Ltd. (Kaide Technology) to establish Guangzhou InnoCare Pharma Tech Co., Ltd., a development center with advanced international standards. Dr. Jisong Cui, co-founder, Chairman, and CEO of InnoCare, said: “We are very pleased to establish the InnoCare Guangzhou Development Center with the Guangzhou Development Zone. It is an important milestone for InnoCare to expand from R&D to manufacture. With China’s aging population, we are in urgent need of more innovative therapies for cancer and autoimmune diseases. The establishment of the InnoCare Guangzhou Development Center will accelerate InnoCare’s innovation in developing more effective and affordable medicines for China and the world.” With a total investment of over 2 billion RMB, the Guangzhou Development Center will cover about 20 acres. Its design, which will meet the GMP requirements of US, Europe, and China, will support InnoCare’s needs from clinical trials to commercial production. The head of the Guangzhou Development Zone Management Committee said: “Guangzhou will further improve and expand the landscape of the biomedical industry. The successful establishment of InnoCare’s facility is of great importance to us and will help Guangzhou build a world-class innovative pharmaceutical industrial cluster. Guangzhou, in-line with the rapid development of InnoCare, will give its strong support to all aspects including fund-raising, management services, and creating a prolific business environment. About InnoCare InnoCare is an emerging biotech company focused on the innovation of novel drugs for immuno-oncology/targeted therapy and autoimmune diseases. Though rooted in China, InnoCare’s mission is to become a global leader in providing patients with safe, effective, and affordable treatments for cancer and autoimmune diseases. Autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus, have high incidence in the China and lack effective treatments. InnoCare combines internal R&D, licensing-in, and international collaboration to drive the development of Best-in-Class drugs. About Guangzhou Kaide Technology Development Co., Ltd. Founded in 1998, Guangzhou Kaide Technology Development Co., Ltd. is a wholly state-owned company under the Guangzhou Development Zone. As the largest technology strategic shareholding platform in the Guangzhou Development Zone, Kaide Technology Co., Ltd. invests in “IAB” and “NEM” industrial projects, such as high-tech enterprises and advanced manufacturing industries. At present, Kaide Technology’s portfolio includes Lejin Display (China) Co., Ltd., BeiGene Bio-Pharmaceutical Co., Ltd., and Xintongyuan Industrial Internet Innovation Center (Guangdong) Co., Ltd. As the director unit of Guangzhou Urban Block Chain Industries, Kaide Technologies will facilitate the development of Guangdong’s block chain industry.
18 Jul, 2018
On July 18, 2018, InnoCare’s ICP-192 was approved for clinical trials by the State Drug Administration. ICP-192, a new class of innovative medicine developed by InnoCare subsidiary Tiancheng Pharmaceuticals, marks the third drug candidate approved for clinical trials in one year. Gastric cancer is the second most common malignant tumor in China, with most patients being diagnosed at the advanced stages. New therapeutic options are needed for advanced-stage patients and those who have become intolerant to standard of care treatments. ICP-192 has an innovative design based on structure-activity optimization. It has shown good safety profile and efficacy in multiple solid tumor animal models. Dr. Jisong Cui, CEO of InnoCare, said: “InnoCare sticks to its mission and strives to provide patients with better therapeutic options. China’s national policies have greatly encouraged innovation. Our R&D team will seize this opportunity to continuously introduce more and better innovative drugs for the benefit of the world.”
07 May, 2018
On April 17, 2018, InnoCare’s innovative R&D department achieved a new milestone when ICP-105, a class 1 chemical drug, was approved for clinical trials by the State Food and  Drug Administration. ICP-105, which was jointly developed by its two subsidiaries, Tianyin Jianhua and Tiancheng Pharmaceuticals, has become InnoCare’s second drug candidate to be approved for clinical trials in just 4 months. Globally, more than 780,000 new cases of liver cancer are diagnosed every year. China has 395,000 new cases annually, with 80% of these patients already in advanced stages. ICP-105, a class 1 innovative drug, is a specific FGFR4 inhibitor with high target selectivity, novel chemical structure, and good drug-like properties. It is expected to have excellent efficacy in solid tumors, such as liver cancers with abnormal FGFR4 signaling. Dr. Jisong Cui, CEO of InnoCare, said: “InnoCare is an innovative drug research and development company. Our R&D team and one-stop new drug R&D platform will continue to introduce more and better innovative drugs, which are urgently needed in the community. With the support of innovative technology, regulatory policy for new drug approval, InnoCare will continue to provide patients with better treatment options." About ICP-105 ICP-105 is a highly specific FGFR4 inhibitor that has been shown to have excellent target selectivity and good drug-like properties. It has significant anti-tumor effects in animal models of hepatocellular carcinoma with abnormal FGFR4 signaling. It is expected to provide safer and more effective treatment for patients with liver cancer.
06 Feb, 2018
On February 6, 2018, Beijing InnoCare Pharma Tech Co., Ltd. (hereinafter referred to as “InnoCare”) announced the completion of financing of US$55 million. This round of investment was led by Vivo Capital and the original shareholder, Shanghai Jianxin Capital. InnoCare is an innovative biotech company rooted in China with a global vision, focusing on the development of innovative drugs for targeted therapy, immuno-oncology and autoimmune diseases. The company's core R&D team consists of members from the world's top 500 companies, such as Pfizer, Bristol-Myers Squibb, Merck, Johnson & Johnson, Bayer, and other top international pharmaceutical companies, and includes well-known scientists from Tsinghua University and Peking University. InnoCare’s Scientific Advisory Board is composed of experts in new drug development and clinical research. InnoCare has a one-stop, full-featured new drug research and development center in Beijing and Nanjing. It has a rich drug research and development pipeline covering a wide range of cancer and autoimmune disease treatment fields. InnoCare’s mission is to use the latest science and technology to discover new drugs that provide safe, effective, and affordable patient treatments. It is expected that a number of new drug products will be put on the market in the future. ICP-022 is a class 1 new drug candidate compound with wholly owned global intellectual property rights. It has completed the phase I clinical trial in Australia and has been approved by the China Food and Drug Administration. Currently, InnoCare has launched a multi-center, multi-indication clinical study. Many other candidate compounds in the company's R&D pipeline are in the IND enabling and clinical research stages. The funds raised in this round of financing will be used to promote clinical trials of multiple projects and to speed up the advancement of drug candidates into clinical studies and to the market. The primary goal is to alleviate China’s growing medical needs and provide patients with better options both at home and abroad. Dr. Jisong Cui, co-founder, Chairman and CEO of InnoCare, said: “At present, we have a number of new drug candidates with wholly-owned intellectual property rights that are or will be under clinical trials. InnoCare’s one-stop R&D platform will continue to provide those patients suffering cancer and autoimmune diseases with innovative medicines that are both highly effective and safe. We are very pleased that InnoCare can be recognized by Vivo Capital. The funds will be used to support clinical development, giving us the opportunity to deliver better drugs to patients in need. By the end of 2018, InnoCare is expected to have milestone clinical trial results as well as 2 to 3 new drug candidates. We will continue to further strengthen our pipeline." Vivo Capital Management Partner and Global Co-CEO Fu Shan said: "We are very honored to be an investor in InnoCare's current round of financing. Vivo Capital has been focusing on investing in high quality companies in the life sciences and health fields, and InnoCare is an innovative and promising new drug discovery platform company, which is in line with our investment philosophy. We look forward to sharing our experience and resources with InnoCare in the next few years to help InnoCare grow into a world's leading innovative drug research and development company." About Vivo Capital Founded in 1996, Vivo Capital is committed to investing in and establishing high-quality companies in the life sciences and health care sectors in the US and China. Vivo Capital manages more than $1.8 billion in funds, and discovers and invests in potential companies through a unique multi-angle investment strategy. In the United States, Vivo mainly invests in companies with innovative therapeutic products. In the Greater China region, it focuses on life sciences and healthcare industry companies that are entering the growth stage. Vivo Capital has offices in Palo Alto, California, and Beijing, Shanghai and Taipei in Greater China. About Shanghai Jianxin Capital Shanghai Jianxin Capital is a venture capital fund specializing in the pharmaceutical and health industry. It has a professional biomedical investment team with rich experience in the medical and financial fields, and forward-looking investment layout based on industry trends for enterprises and investors.
19 Dec, 2017
On December 19, 2017, ICP-022, an innovative pharmaceutics with wholly-owned intellectual property rights, was approved by the State Food and Drug Administration (CFDA) for clinical trials against systemic lupus erythematosus (SLE) and rheumatoid arthritis. Autoimmune diseases such as SLE and RA are serious threats to human health. More than 2 million Chinese patients still lack effective treatments. ICP-022 is a highly specific BTK inhibitor with excellent efficacy in SLE and RA models. It has shown good tolerance and safety in phase I clinical trial on healthy subjects in Australia. It is expected to provide safe and effective treatment options for patients with SLE and RA. Dr. Jisong Cui, co-founder, chairman and CEO of InnoCare, said: “The clinical trial of ICP-022 has been approved, which means that the first research product from InnoCare, which was established 2 years ago, will soon enter clinical development in China. The reform of domestic pharmaceutical policy and the steady growth of the pharmaceutical market are crucial to the development of InnoCare. We are very happy to receive this approval and look forward to officially launching the clinical research of ICP-022 in mainland China." About ICP-022 ICP-022 is a highly specific BTK inhibitor with excellent kinase selectivity and drug-like properties. Good safety and pharmacokinetic properties have been shown in clinical trials in Australia. It has good prospects for the treatment of autoimmune diseases.
21 Sep, 2016
September 20-21, 2016, Dr. Jasmine Cui, President & CEO of InnoCare Pharma was invited to be the Chair and gave an opening speech at the conference. Bio Partnering APAC 2016 is designed to be a premium collaborative platform for big pharmas, biotechs, investors and other stake holders in pharma industry to meet, communicate and establish partnership on pharma R&D. Bio Partnering APAC 2016 is hosted by Shine Consultant and supported by Sino-American Pharmaceutical Professional Association (SAPA), CBA, Taiwan Bio Industry Organization. Senior executives from pharmaceutical and biopharma companies  including Pfizer, Merck, Novartis, Roche, Sanofi-Aventis, Eli Lilly, Johnson & Johnson and Hutchsion Medi Pharma had intensive discussion on hot topics in Pharma R&D. Experts from investment companies or consulting firms such as McKinsey, Morningside Asia Venture, Lilly Asia Venture Fund also joined the discussion.